Montgomery County (MOCO), Maryland, sits at the epicenter of biopharma growth, investment, and innovation that makes the BioHealth Capital Region (BHCR) one of the top bio clusters in the world.
After spending the past five years fostering economic development in Montgomery County, Sarah Miller is turning her attention to the biopharma industry and the BioHealth Capital Region. Starting May 3, Miller joined BioHealth Innovation, Inc. as Vice President of Economic Development.
Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.
The traditional two-needle approach to filtering injectable glass ampoule-based medications is unsafe to health care providers and patients. The process is also time-consuming and costly.
Founded by former NASA mission specialist Bruce K. Redding Jr., Transdermal Specialties Global (TSG) is attempting to revolutionize drug delivery. Redding, who holds over 60 patents, is the inventor of microencapsulation technology, which his company is leveraging to develop an insulin patch as a non-invasive, needleless method for diabetes treatment.
When AstraZeneca (AZ) announced in 2019 that it was officially retiring the MedImmune brand, questions naturally arose about whether the U.K. pharma giant would continue the legacy MedImmune support for the BioHealth Capital Region’s (BHCR) life science ecosystem.
Kevin Combs, the CEO of Molecular Biologicals out of Charlottesville, Virginia, had a front-row seat to the BioHealth Capital Region’s (BHCR) ascendancy. He is now a vital part of the rise of CVille, the life science cluster within the BHCR that is blossoming in and around the University of Virginia (UVA).
Rockville, Maryland’s Autonomous Therapeutics (Autonomous) is a rapidly expanding biotech developing the next generation of antivirals and therapeutics.
Personalized and regenerative medicines are promising but they are complex to develop and require highly-flexible advanced manufacturing techniques that are still too manually intensive and costly.
Tia Lyles-Williams, the founder & CEO of LucasPye BIO (LPB) and HelaPlex, is on a mission to lower development and manufacturing costs for emerging life science companies while bringing greater diversity to the life science industry.
